How Does Depo-Provera Affect Bone Density?
Depo-Provera (medroxyprogesterone acetate injectable suspension) suppresses estrogen production, which can reduce bone mineral density (BMD). Studies show users lose BMD at the spine, hip, and forearm, with average annual losses of 0.5-2.4% during the first year and smaller losses (0.3-0.6%) in subsequent years.[1][2] This effect is reversible in most adolescents and adults after stopping use, with BMD recovering within 2-5 years.[1]
Who Faces the Highest Risk?
Adolescents (12-18 years) experience greater BMD loss due to ongoing bone growth—up to 7.5% at the lumbar spine over 4 years—prompting FDA warnings against use beyond 2 years unless other options fail.[1][3] Postmenopausal women and long-term users (>5 years) also risk more significant, slower-recovering losses. Factors like low body weight, smoking, alcohol use, or calcium/vitamin D deficiency amplify risk.[2]
Does the Loss Become Permanent?
Reversibility varies: most regain BMD after discontinuation, but some adults show partial or no recovery at the hip after 5+ years.[1][2] No direct link exists to higher fracture rates in studies, though theoretical fracture risk rises with substantial BMD loss.[3]
What Do Guidelines Recommend for Monitoring?
The FDA requires a black box warning on BMD loss. Providers should assess risks/benefits yearly, consider baseline DEXA scans for long-term users, and recommend calcium (1,200 mg/day) and vitamin D (at least 400 IU/day) supplements. Switch to alternatives if BMD declines significantly.[1][3]
Alternatives with Lower Bone Risk